EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Multizentrische StudieRandomisierte kontrollierte StudieOpen Access

Effect of PCSK9 Inhibition With Alirocumab in Patients With Probable Familial Hypercholesterolemia or Type III Hyperlipoproteinemia: Results From the ODYSSEY OUTCOMES Trial

Gregory P Geba, Kusha A Mohammadi iD, Amy Damask iD, Charles Paulding iD, Luca A Lotta, George Hindy, Robert Pordy iD, Garen Manvelian iD, Michael D Shapiro iD, Vera A Bittner iD, Deepak L Bhatt iD, Michael Szarek iD und 3 weitere

Journal of the American Heart Association · 02.09.2025 · 14 (17)

DOI: 10.1161/jaha.124.041190 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Journal of the American Heart Association, erschienen am 02.09.2025. Verfasst von Gregory P Geba und 14 weiteren Autor:innen. Beteiligte Einrichtung: Regeneron Pharmaceuticals, Inc. Tarrytown NY USA. Hauptthemen laut MEDLINE: Acute Coronary Syndrome, Antibodies, Monoclonal, Humanized, Anticholesteremic Agents, Hyperlipoproteinemia Type II. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

In this post hoc analysis of the ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) trial, we evaluated the efficacy of alirocumab in patients with probable heterozygous familial hypercholesterolemia (HeFH) or type III hyperlipoproteinemia (T3HLP).

Methods

Patients had clinical HeFH if baseline low‐density lipoprotein cholesterol was ≥250 mg/dL and the qualifying acute coronary syndrome event occurred before age 55 (men) or 60 years (women), or if baseline low‐density lipoprotein cholesterol was ≥330 mg/dL. Patients had T3HLP if the ratio, validated using the UK Biobank database, of non–high‐density lipoprotein cholesterol/apolipoprotein B was >2.6. Genetic variation affecting low‐density lipoprotein cholesterol levels (HeFH) and APOE genotypes (T3HLP) was assessed in a pharmacogenomics subgroup.

Results

In total, 5.8% of patients from ODYSSEY OUTCOMES and 5.9% from the pharmacogenomics subgroup qualified as having clinical HeFH. In the pharmacogenomics subgroup, 295 patients (2.5%) had genetically confirmed HeFH; 45.8% also qualified as having clinical HeFH. Lipid responses and clinical benefits of alirocumab were similar in all patients with or without HeFH. In the ODYSSEY OUTCOMES cohort, 30 of 18 924 patients (0.16%) were identified as having T3HLP. The pharmacogenomics subgroup included 13 of these 30 patients, of whom 7 (53.8%) were APOE2/2 homozygotes. Lipid responses to alirocumab in patients with T3HLP were comparable with those in the general population. In those with genetic dyslipidemia, adverse event incidence was similar to the overall group.

Conclusions

In ODYSSEY OUTCOMES, individuals with HeFH were common while those with T3HLP were rare. In their lipid responses, carriers of both conditions benefited from alirocumab. Registration URL: https://clinicaltrials.gov ; Unique identifier: NCT01663402.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Acute Coronary SyndromeAntibodies, Monoclonal, HumanizedAnticholesteremic AgentsHyperlipoproteinemia Type IIHyperlipoproteinemia Type IIIPCSK9 InhibitorsSerine Proteinase InhibitorsAgedFemaleHumansMaleMiddle AgedApolipoproteins EBiomarkersCholesterol, LDLHeterozygoteProprotein Convertase 9Treatment Outcome

Stichwörter der Autor:innen

LDL‐Calirocumabheterozygous familial hypercholesterolemiatype III hyperlipoproteinemia

Substanzen

alirocumabAntibodies, Monoclonal, HumanizedAnticholesteremic AgentsApolipoproteins EBiomarkersCholesterol, LDLPCSK9 InhibitorsPCSK9 protein, humanProprotein Convertase 9Serine Proteinase Inhibitors

Autor:innen und Institutionen

  • Regeneron Pharmaceuticals, Inc. Tarrytown NY USA.
  • Section of Cardiovascular Medicine, Department of Internal Medicine Wake Forest School of Medicine Winston-Salem NC USA.
  • Division of Cardiovascular Disease University of Alabama at Birmingham Birmingham AL USA.
  • Mount Sinai Fuster Heart Hospital Icahn School of Medicine at Mount Sinai New York NY USA.
  • CPC Clinical Research and Division of Cardiology University of Colorado School of Medicine Aurora CO USA.
  • State University of New York Downstate Health Sciences University Brooklyn NY USA.

ORCID-Profile: Kusha A Mohammadi, Amy Damask, Charles Paulding, Robert Pordy, Garen Manvelian, Michael D Shapiro, Vera A Bittner, Deepak L Bhatt, Michael Szarek, Gregory G Schwartz, Ph Gabriel Steg, Sergio Fazio

Zitieren

APA

Geba, G. P., Mohammadi, K. A., Damask, A., Paulding, C., Lotta, L. A., Hindy, G., Pordy, R., Manvelian, G., Shapiro, M. D., Bittner, V. A., Bhatt, D. L., Szarek, M., Schwartz, G. G., Steg, P. G., & Fazio, S. (2025). Effect of PCSK9 Inhibition With Alirocumab in Patients With Probable Familial Hypercholesterolemia or Type III Hyperlipoproteinemia: Results From the ODYSSEY OUTCOMES Trial. Journal of the American Heart Association, 14(17). https://doi.org/10.1161/jaha.124.041190

Vancouver

Geba GP, Mohammadi KA, Damask A, Paulding C, Lotta LA, Hindy G, et al. Effect of PCSK9 Inhibition With Alirocumab in Patients With Probable Familial Hypercholesterolemia or Type III Hyperlipoproteinemia: Results From the ODYSSEY OUTCOMES Trial. Journal of the American Heart Association. 2025;14(17). doi:10.1161/jaha.124.041190

BibTeX
@article{Geba2025,
  author = {Geba, Gregory P and Mohammadi, Kusha A and Damask, Amy and Paulding, Charles and Lotta, Luca A and Hindy, George and Pordy, Robert and Manvelian, Garen and Shapiro, Michael D and Bittner, Vera A and Bhatt, Deepak L and Szarek, Michael and Schwartz, Gregory G and Steg, Ph Gabriel and Fazio, Sergio},
  title = {Effect of PCSK9 Inhibition With Alirocumab in Patients With Probable Familial Hypercholesterolemia or Type III Hyperlipoproteinemia: Results From the ODYSSEY OUTCOMES Trial},
  journal = {Journal of the American Heart Association},
  year = {2025},
  volume = {14},
  number = {17},
  doi = {10.1161/jaha.124.041190}
}
Kostenlos starten →